ArticleJournal of translational medicine2026
Monitoring of dual-drug combination therapy in pediatric epilepsy patients: a machine learning model for simultaneous VPA-LEV concentration-dose prediction.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo better meet the therapeutic demand in pediatric epilepsy patients (PEPs) receiving combined valproic acid (VPA) and levetiracetam (LEV) (therapeutic ranges: VPA 50–100 μg/mL; LEV 6–20 μg/mL.), We developed a dual-predictive machine learning (ML) model that integrates concentration monitoring with dose recommendation capabilities, serving as an adjunct tool for therapeutic drug monitoring (TDM).
methodsA retrospectively collected dataset comprising 497 paired concentration samples from 402 PEPs was used to train (i) classification models that predict adequacy of VPA and LEV concentrations and (ii) regression models that recommend individualised daily doses. Model explainability was interrogated with SHapley Additive exPlanations (SHAP) analysis to delineate concentration-dose covariates.
resultsAmong nine nonlinear ML algorithms, the Extra-Trees classifier achieved optimal performance for concentration adequacy prediction, delivering test-set accuracies and AUCs of 0.74 and 0.75 for VPA, and 0.75 and 0.75 for LEV, respectively. SHAP analysis elucidated body weight-normalized daily dose, blood urea nitrogen/creatinine (BUN/CREA) ratio, and platelet count (PLT) were identified as shared critical covariates. Serum uric acid (UA) exhibited LEV-specific positive regulation (SHAP rank 2, contribution 16.2%). For dose recommendation, an XGBoost multi-output regressor yielded test-set R2 values of 0.60 for both VPA and LEV daily dose. Body weight dominated dose predictions (VPA 70.2%; LEV 62.8%), followed by respective trough concentrations (VPA 7.1%; LEV 14.7%).
conclusionThis dual-prediction model enables simultaneous concentration monitoring and dose recommendation of VPA and LEV, offering a data-driven decision-support tool for personalised therapy in PEPs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.